Capecitabine, Megestrol, Toremifene, Vinorelbine
Multiple indications across four chemotherapy agents: capecitabine for advanced breast cancer and colorectal cancer; megestrol for hormone-dependent advanced breast cancer; toremifene for hormone-dependent metastatic breast cancer in post-menopausal patients; vinorelbine for locally advanced/metastatic non-small cell lung cancer and advanced breast cancer.
Access path
- Nov 2014Recommended · restricted
- PBS listing · Unrestricted
From the public summary
3.1 The PBAC agreed with the MOGA view that the patterns of use of these drugs is unlikely to be influenced by the PBS restriction level given the long history of PBS- listing and emergence of more targeted therapies in recent times.PSD · Nov 2014
Cost-effectiveness
Not modelled — this is a restriction level change request for existing PBS-listed drugs, not a new submission with economic evaluation.
Decision context
PopulationPatients with advanced/metastatic breast cancer, colorectal cancer, oesophago-gastric cancer, and non-small cell lung cancer (various lines of therapy as per existing PBS restrictions).
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2014 | Recommended · restricted | — | — | — |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to later-line therapy across multiple cancer types; TGA labels do not specify treatment line limitations.